--- title: "Cardinal Health | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 65.63 B" type: "News" locale: "en" url: "https://longbridge.com/en/news/274965538.md" datetime: "2026-02-05T11:49:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274965538.md) - [en](https://longbridge.com/en/news/274965538.md) - [zh-HK](https://longbridge.com/zh-HK/news/274965538.md) --- # Cardinal Health | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 65.63 B Revenue: As of FY2026 Q2, the actual value is USD 65.63 B, beating the estimate of USD 65.24 B. EPS: As of FY2026 Q2, the actual value is USD 1.97, beating the estimate of USD 1.92. EBIT: As of FY2026 Q2, the actual value is USD 795 M. ### Financial Performance Summary (Second Quarter Fiscal Year 2026) #### Overall Performance - **GAAP Operating Earnings**: Increased 29% to $707 million, compared to $549 million in Q2 FY25. - **Non-GAAP Operating Earnings**: Increased 38% to $877 million, up from $635 million in Q2 FY25. - **Net Earnings Attributable to Cardinal Health, Inc. (GAAP)**: Increased 17% to $467 million, from $400 million in Q2 FY25. - **Non-GAAP Net Earnings Attributable to Cardinal Health, Inc.**: Increased 33% to $624 million, from $468 million in Q2 FY25. - **Gross Margin (GAAP)**: Rose 23% to $2,397 million, from $1,941 million in Q2 FY25. - **Distribution, Selling, General and Administrative Expenses (GAAP)**: Increased 15% to $1,504 million, from $1,306 million in Q2 FY25. - **Interest Expense, Net (GAAP)**: Was $88 million, compared to $35 million in Q2 FY25. - **Provision for Income Taxes (GAAP)**: Increased 45% to $159 million, from $110 million in Q2 FY25. - **Effective Tax Rate (GAAP)**: Was 25.2%, compared to 21.4% in Q2 FY25. - **Non-GAAP Effective Tax Rate**: Remained at 21.4% for both Q2 FY26 and Q2 FY25. - **Weighted-Average Number of Common Shares Outstanding (Diluted)**: Decreased to 237 million, from 243 million in Q2 FY25. #### Segment Performance (Second Quarter Fiscal Year 2026) - **Pharmaceutical and Specialty Solutions**: - **Segment Profit**: Increased 29% to $687 million, driven by contributions from brand and specialty products, MSO platforms acquisition, and positive generics program performance. - **Segment Profit Margin**: Was 1.13%, up from 1.04% in Q2 FY25. - **Global Medical Products and Distribution**: - **Segment Profit**: Increased 106% to $37 million, driven by growth from existing customers and cost optimization initiatives, partially offset by tariffs. - **Segment Profit Margin**: Was 1.14%, up from 0.57% in Q2 FY25. - **Other (includes Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics)**: - **Segment Profit**: Increased 52% to $179 million, driven by growth across the three operating segments. - **Segment Profit Margin**: Was 10.38%, up from 9.20% in Q2 FY25. #### Cash Flow (Second Quarter Fiscal Year 2026) - **Net Cash Provided by Operating Activities**: Was $686 million, compared to net cash used in operating activities of -$396 million in Q2 FY25. - **Net Cash Used in Investing Activities**: Was -$1,980 million, compared to -$976 million in Q2 FY25. - **Net Cash Provided by/(Used in) Financing Activities**: Was -$519 million, compared to $2,327 million in Q2 FY25. - **Non-GAAP Adjusted Free Cash Flow**: Was $543 million, compared to -$250 million in Q2 FY25. ### Financial Performance Summary (Year-to-Date Fiscal Year 2026) #### Overall Performance - **GAAP Operating Earnings**: Increased 23% to $1,375 million, compared to $1,117 million in YTD FY25. - **Non-GAAP Operating Earnings**: Increased 38% to $1,734 million, up from $1,260 million in YTD FY25. - **Net Earnings Attributable to Cardinal Health, Inc. (GAAP)**: Increased 12% to $917 million, from $816 million in YTD FY25. - **Non-GAAP Net Earnings Attributable to Cardinal Health, Inc.**: Increased 33% to $1,235 million, from $927 million in YTD FY25. - **Gross Margin (GAAP)**: Rose 23% to $4,716 million, from $3,843 million in YTD FY25. - **Distribution, Selling, General and Administrative Expenses (GAAP)**: Increased 15% to $2,965 million, from $2,583 million in YTD FY25. - **Interest Expense, Net (GAAP)**: Was $168 million, compared to $67 million in YTD FY25. - **Provision for Income Taxes (GAAP)**: Increased 29% to $303 million, from $234 million in YTD FY25. - **Effective Tax Rate (GAAP)**: Was 24.7%, compared to 22.2% in YTD FY25. - **Non-GAAP Effective Tax Rate**: Was 21.7%, compared to 22.2% in YTD FY25. - **Weighted-Average Number of Common Shares Outstanding (Diluted)**: Decreased to 238 million, from 243 million in YTD FY25. #### Segment Performance (Year-to-Date Fiscal Year 2026) - **Pharmaceutical and Specialty Solutions**: - **Segment Profit**: Increased 28% to $1,354 million. - **Segment Profit Margin**: Was 1.13%, up from 1.07% in YTD FY25. - **Global Medical Products and Distribution**: - **Segment Profit**: Showed significant growth to $83 million. - **Segment Profit Margin**: Was 1.29%, up from 0.41% in YTD FY25. - **Other**: - **Segment Profit**: Increased 55% to $345 million. - **Segment Profit Margin**: Was 10.25%, up from 8.99% in YTD FY25. #### Cash Flow (Year-to-Date Fiscal Year 2026) - **Net Cash Provided by Operating Activities**: Was $1,659 million, compared to net cash used in operating activities of -$2,043 million in YTD FY25. - **Net Cash Used in Investing Activities**: Was -$2,122 million, compared to -$1,064 million in YTD FY25. - **Net Cash Provided by/(Used in) Financing Activities**: Was -$629 million, compared to $1,787 million in YTD FY25. - **Non-GAAP Adjusted Free Cash Flow**: Was $1,828 million, compared to -$1,611 million in YTD FY25. ### Outlook / Guidance (Fiscal Year 2026) Cardinal Health (卡地纳健康) raised its fiscal year 2026 non-GAAP diluted EPS guidance to a range of $10.15 to $10.35, reflecting a 23% to 26% growth. This guidance includes raised and narrowed Pharmaceutical and Specialty Solutions segment profit growth to 20% to 22%, Global Medical Products and Distribution segment profit raised to approximately $150 million, and Other segment profit growth raised to 33% to 35%. Additionally, the non-GAAP effective tax rate is decreased to 21% to 23%, and diluted weighted average shares outstanding are decreased to 237 million to 238 million. ### Other Key Metrics - **Share Repurchase**: Cardinal Health (卡地纳健康) completed an additional $375 million accelerated share repurchase program in Q2 FY26, bringing year-to-date share repurchases to $750 million. - **Leverage**: Cardinal Health (卡地纳健康) reached its targeted leverage range of 2.75x to 3.25x Adjusted Debt to EBITDA, achieving 3.2x leverage as of December 31, 2025. - **Acquisitions**: The Specialty Alliance platform completed the acquisition of Solaris Health, a leading Urology MSO, on November 3rd. - **Product/Service Initiatives**: The at-Home Solutions business introduced the ContinuCare™ Pathway program and announced a partnership with Publix Super Markets Inc. ### Related Stocks - [CAH.US](https://longbridge.com/en/quote/CAH.US.md) ## Related News & Research - [ATS Reports Fourth Quarter Fiscal 2026 Results | ATS Stock News](https://longbridge.com/en/news/287895609.md) - [Reducto Named to Redpoint's 2026 InfraRed 100](https://longbridge.com/en/news/287832370.md) - [District Announces Q3 2026 Results | DMXCF Stock News](https://longbridge.com/en/news/288010458.md) - [CRACKER BARREL FISCAL 2026 THIRD QUARTER CONFERENCE CALL | CBRL Stock News](https://longbridge.com/en/news/287630743.md) - [FingerMotion Reports FY 2026 Financial Results | FNGR Stock News](https://longbridge.com/en/news/288117993.md)